Shanghai Pharmaceuticals' Unit Gets Approval for Eltrombopag Ethanolamine Tablets' Registration

MT Newswires Live07-24

Shanghai Pharmaceuticals Holding's (SHA:601607, HKG:2607) unit, Changzhou Pharmaceutical Factory, received a drug registration certificate from Chinese drug regulator National Medical Products Administration for its eltrombopag ethanolamine tablets, the company said in its filing on the Shanghai Stock Exchange.

The drug is used as a treatment for patients with chronic immune (idiopathic) thrombocytopenia who have not responded well to treatments such as glucocorticoids and immunoglobulins in the past.

The pharmaceutical company invested 21.6 million yuan into the research and development of the drug, according to the Wednesday filing.

The company's shares rose more than 1% on the Shanghai bourse.

Price (HKD): $19.53, Change: $+0.25, Percent Change: +1.30%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2453604153?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-07-24 12:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2453604153","market":"us","top_or_hot":-1,"title":"Shanghai Pharmaceuticals' Unit Gets Approval for Eltrombopag Ethanolamine Tablets' Registration","media":"MT Newswires Live","content":"<html><body><p> Shanghai Pharmaceuticals Holding's (SHA:601607, HKG:2607) unit, Changzhou Pharmaceutical Factory, received a drug registration certificate from Chinese drug regulator National Medical Products Administration for its eltrombopag ethanolamine tablets, the company said in its filing on the Shanghai Stock Exchange.</p><p>The drug is used as a treatment for patients with chronic immune (idiopathic) thrombocytopenia who have not responded well to treatments such as glucocorticoids and immunoglobulins in the past.</p><p>The pharmaceutical company invested 21.6 million yuan into the research and development of the drug, according to the Wednesday filing.</p><p>The company's shares rose more than 1% on the Shanghai bourse.</p><p>Price (HKD): $19.53, Change: $+0.25, Percent Change: +1.30%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai Pharmaceuticals' Unit Gets Approval for Eltrombopag Ethanolamine Tablets' Registration</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai Pharmaceuticals' Unit Gets Approval for Eltrombopag Ethanolamine Tablets' Registration\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-24 12:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shanghai Pharmaceuticals Holding's (SHA:601607, HKG:2607) unit, Changzhou Pharmaceutical Factory, received a drug registration certificate from Chinese drug regulator National Medical Products ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4023","symbol_name":"应用软件","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2453604153","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2453604153","pubTimestamp":1721795161,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Shanghai Pharmaceuticals Holding's  unit, Changzhou Pharmaceutical Factory, received a drug registration certificate from Chinese drug regulator National Medical Products Administration for its eltrombopag ethanolamine tablets, the company said in its filing on the Shanghai Stock Exchange.The drug is used as a treatment for patients with chronic immune  thrombocytopenia who have not responded well to treatments such as glucocorticoids and immunoglobulins in the past.The pharmaceutical company invested 21.6 million yuan into the research and development of the drug, according to the Wednesday filing.The company's shares rose more than 1% on the Shanghai bourse.Price : $19.53, Change: $+0.25, Percent Change: +1.30%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"601607":"上海医药","BK4023":"应用软件","02607":"上海医药","BK4585":"ETF&股票定投概念","BK1197":"保健护理产品经销商","BK4526":"热门中概股","HKD":"尚乘数科","BK0099":"上海本地重组","BK0028":"国家队","BK4588":"碎股","BK0188":"融资融券","BK0020":"浦东新区","BK0187":"一线龙头","BK0184":"上海国资改革","BK0209":"零售","BK0183":"MSCI概念","BK0175":"白马股","BK0012":"证金概念","BK0196":"行业龙头","BK0097":"医药电商"},"translate_title":"上海医药旗下单位获艾曲泊帕乙醇胺片注册批件","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"601607":0.9,"HKD":1,"02607":0.9},"content_text":"Shanghai Pharmaceuticals Holding's (SHA:601607, HKG:2607) unit, Changzhou Pharmaceutical Factory, received a drug registration certificate from Chinese drug regulator National Medical Products Administration for its eltrombopag ethanolamine tablets, the company said in its filing on the Shanghai Stock Exchange.The drug is used as a treatment for patients with chronic immune (idiopathic) thrombocytopenia who have not responded well to treatments such as glucocorticoids and immunoglobulins in the past.The pharmaceutical company invested 21.6 million yuan into the research and development of the drug, according to the Wednesday filing.The company's shares rose more than 1% on the Shanghai bourse.Price (HKD): $19.53, Change: $+0.25, Percent Change: +1.30%","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2453604153"}